NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.01. View Eiger Biopharmaceuticals' Earnings History.

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eiger Biopharmaceuticals.

6 brokerages have issued twelve-month price objectives for Eiger Biopharmaceuticals' shares. Their forecasts range from $10.72 to $47.00. On average, they expect Eiger Biopharmaceuticals' share price to reach $28.54 in the next year. This suggests a possible upside of 102.6% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

Media stories about EIGR stock have trended somewhat positive on Tuesday, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eiger Biopharmaceuticals earned a news impact score of 1.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 475,400 shares, a decrease of 8.9% from the December 15th total of 521,800 shares. Based on an average daily trading volume, of 159,900 shares, the days-to-cover ratio is presently 3.0 days. Currently, 2.2% of the shares of the company are sold short. View Eiger Biopharmaceuticals' Current Options Chain.

Some companies that are related to Eiger Biopharmaceuticals include Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Sangamo Therapeutics (SGMO), Mesoblast (MESO), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Vericel (VCEL), Cellectis (CLLS), GENFIT S A/ADR (GNFT) and Adverum Biotechnologies (ADVM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Concert Pharmaceuticals (CNCE), Amarin (AMRN), Celldex Therapeutics (CLDX), Exelixis (EXEL) and Catalyst Pharmaceuticals (CPRX).

Eiger Biopharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tocqueville Asset Management L.P. (0.21%) and Sanders Morris Harris LLC (0.19%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Joanne Quan, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

EIGR stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC and Tocqueville Asset Management L.P.. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EIGR stock can currently be purchased for approximately $14.09.

Eiger Biopharmaceuticals has a market capitalization of $345.21 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.View Additional Information About Eiger Biopharmaceuticals.

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]